Abstract: FR-PO262
Cancer Screening for Dialysis Patients
Session Information
- Onconephrology: From AKI to CKD and Everything in Between
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Onconephrology
- 1700 Onconephrology
Authors
- Ng, Wern Lynn, UPMC Harrisburg, Harrisburg, Pennsylvania, United States
- Calderon Barahona, Gabriela M., UPMC Harrisburg, Harrisburg, Pennsylvania, United States
- Girón, Carlos Fernando Ortega Carlos Fernando Ortega Girón, UPMC Harrisburg, Harrisburg, Pennsylvania, United States
- Calderon Martinez, Evelyn J., UPMC Harrisburg, Harrisburg, Pennsylvania, United States
- Cuevas Velazquez, Adan Martin, UPMC Harrisburg, Harrisburg, Pennsylvania, United States
- Guzman, Adalberto E., UPMC Harrisburg, Harrisburg, Pennsylvania, United States
- Afreen, Amna, UPMC Harrisburg, Harrisburg, Pennsylvania, United States
- Htoo, Moe Pwint Phyu, UPMC Harrisburg, Harrisburg, Pennsylvania, United States
- Khor, Si Yuan, Michigan State University, East Lansing, Michigan, United States
- Atrash, Anas, UPMC Harrisburg, Harrisburg, Pennsylvania, United States
Background
Routine cancer screening is not recommended for end stage renal disease (ESRD) patients due to their high mortality rate. The current status of cancer screening in this population remains uncertain, and routine screening is deemed cost-ineffective. False-positive test outcomes may lead to unwarranted medical interventions, overtreatment, and psychological distress, highlighting the need for careful consideration in implementing such screening measures.
Methods
Among 340 ESRD patients at UPMC Harrisburg, 136 were ineligible, resulting in a cohort of 204 patients. Descriptive analysis reported categorical variables as number (percent). Group differences were assessed using chi-square tests, employing Fisher exact test for frequencies ≤5. A p-value <0.05 indicated statistical significance. SAS 9.4 (SAS Institute, Cary NC) was used for all analyses.
Results
Among the cancer screening rates examined, including breast cancer, colon cancer, prostate cancer, and cervical cancer, there was no statistically significant difference observed between patients who died from cancer-related causes and those who died from non-cancer related causes. However, it is worth noting that the screening rate for lung cancer displayed a statistically significant difference between these two groups.
Conclusion
Cancer screening in ESRD patients should be tailored on anticipated survival, transplant eligibility, and cancer risk. However, this study is limited by small sample sizes. Larger patient cohorts are needed to provide more representative results. A personalized approach to cancer screening, considering specific risk factors and projected lifespan, is crucial in ESRD patients. Further retrospective studies are necessary.